Study of pegcetacoplan for C3G or IC-MPGN kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well pegcetacoplan works and how safe it is for people with two rare kidney diseases, called C3G and IC-MPGN. It will help doctors understand how the medicine helps patients in real life, outside of a strict clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with C3G or primary IC-MPGN (both are kidney diseases).
- You have already started or are planning to start treatment with pegcetacoplan (the medicine being studied).
- You are not receiving another experimental treatment for C3G or IC-MPGN at the same time.
- You have not already taken part in an interventional study (a trial that tests a medicine) with pegcetacoplan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
This study looks at how well iptacopan works for people with C3G, a kidney disease. It aims to see if the treatment is safe and effective, and includes people who have already taken iptacopan.
This trial tests pegcetacoplan in children (ages 12–17) with paroxysmal nocturnal hemoglobinuria (PNH), a condition that can cause ongoing blood cell breakdown. The goal is to see if the medicine can improve anemia related to PNH.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This study tracks adults with C3G (a rare kidney disease where the immune system damages the filtering units) who have already received iptacopan (a new medicine) through an early access program in Spain. Researchers want to understand how well this treatment works and its safety in real-world patients.
This study follows people in Russia with C3 glomerulopathy or IC-MPGN to understand how these kidney diseases progress over time. It does not test a new treatment, but gathers information from medical records and check-ups to learn more about the conditions.
Hear when a new C3 Glomerulopathy (C3G) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.